Literature DB >> 8615634

Loss of heterozygosity in chromosome 4q12-q13 in hepatocellular carcinoma in southern African blacks.

M Leon1, M C Kew.   

Abstract

Paired samples of hepatocellular carcinoma and non-tumorous hepatic tissue from 12 southern African blacks were examined for loss of heterozygosity at two loci (D4S409 and D4S392) in chromosome 4q12-q13 (mapping to the same region as the locus for the gene for alpha-fetoprotein). Deoxyribonucleic acid was extracted from carcinoma and non-tumorous tissues and amplified using the polymerase chain reaction. The primers used were based on flanking regions of minisatellite DNA specific for the loci. Products of PCR amplification were separated by denaturing polyacrylamide gel electrophoresis and analysed for allelic losses. At the D4S409 locus one of seven informative samples showed loss of heterozygosity, whereas none of eight informative samples showed loss of heterozygosity at the D4S392 locus. If these findings are considered together with those previously reported in hepatocellular carcinomas from black Africans, the prevalence of loss heterozygosity in chromosome 4q12-q13 in hepatocellular carcinoma in southern African blacks (33 per cent) is the same as that in tumours from Japanese patients. Loss of heterozygosity at chromosome 4q12-q13 is infrequent during hepatocellular carcinogenesis in southern African blacks.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8615634

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Genetic alterations in hepatocellular carcinomas: association between loss of chromosome 4q and p53 gene mutations.

Authors:  A Rashid; J S Wang; G S Qian; B X Lu; S R Hamilton; J D Groopman
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

Review 2.  The homeobox only protein homeobox (HOPX) and colorectal cancer.

Authors:  Keishi Yamashita; Hiroshi Katoh; Masahiko Watanabe
Journal:  Int J Mol Sci       Date:  2013-11-25       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.